| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8337824 | VIFOR PHARMA | Linear polyol stabilized polyfluoroacrylate compositions |
May, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8287847 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(25 days ago) | |
| US8778324 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(25 days ago) | |
| US8889115 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(25 days ago) | |
| US8475780 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(25 days ago) | |
| US10485821 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(25 days ago) | |
| US7556799 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Feb, 2025
(10 months from now) | |
| US8216560 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2027
(2 years from now) | |
| US8282913 | VIFOR PHARMA | Ion binding polymers and uses thereof |
May, 2027
(3 years from now) | |
| US8147873 | VIFOR PHARMA | Methods and compositions for treatment of ion imbalances |
Jun, 2028
(4 years from now) | |
| US9925212 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
| US11123363 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
| US9492476 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
Veltassa is owned by Vifor Pharma.
Veltassa contains Patiromer Sorbitex Calcium.
Veltassa has a total of 13 drug patents out of which 5 drug patents have expired.
Expired drug patents of Veltassa are:
- US8287847
- US8778324
- US8889115
- US8475780
- US10485821
Veltassa was authorised for market use on 02 October, 2023.
Veltassa is available in powder;oral dosage forms.
Veltassa can be used as treatment of hyperkalemia.
Drug patent challenges can be filed against Veltassa from 22 October, 2019.
The generics of Veltassa are possible to be released after 08 October, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 02, 2026 |
| New Strength(NS) | Oct 02, 2026 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Treatment: Treatment of hyperkalemia
Dosage: POWDER;ORAL
VELTASSA family patents
